ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth

(2012) C. Claus et al.   CANCER RESEARCH

Markers of B-Cell Activation in Relation to Risk of Non-Hodgkin Lymphoma

(2012) A. J. De Roos et al.   CANCER RESEARCH

CD70–CD27 Interaction Augments CD8+ T-Cell Activation by Human Epidermal Langerhans Cells

(2012) Marta E. Polak et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand

(2009) A. Wyzgol et al.   JOURNAL OF IMMUNOLOGY

Enhanced formation and survival of CD4+CD25hiFoxp3+T-cells in chronic lymphocytic leukemia

(2009) Margot Jak et al.   LEUKEMIA & LYMPHOMA

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia

(2008) A. W. Ho et al.   BLOOD

Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF

(2008) Hiroki Yano et al.   BRITISH JOURNAL OF HAEMATOLOGY

Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker

(2008) E. Oflazoglu et al.   CLINICAL CANCER RESEARCH

Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70

(2008) J. A. McEarchern et al.   CLINICAL CANCER RESEARCH